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Abstract: A plethora of research has implicated hundreds of putative biomarkers for depres-
sion, but has not yet fully elucidated their roles in depressive illness or established what is 
abnormal in which patients and how biologic information can be used to enhance diagnosis, 
treatment and prognosis. This lack of progress is partially due to the nature and heterogeneity 
of depression, in conjunction with methodological heterogeneity within the research literature 
and the large array of biomarkers with potential, the expression of which often varies according 
to many factors. We review the available literature, which indicates that markers involved in 
inflammatory, neurotrophic and metabolic processes, as well as neurotransmitter and neuroen-
docrine system components, represent highly promising candidates. These may be measured 
through genetic and epigenetic, transcriptomic and proteomic, metabolomic and neuroimaging 
assessments. The use of novel approaches and systematic research programs is now required 
to determine whether, and which, biomarkers can be used to predict response to treatment, 
stratify patients to specific treatments and develop targets for new interventions. We conclude 
that there is much promise for reducing the burden of depression through further developing 
and expanding these research avenues.
Keywords: mood disorder, major depressive disorder, inflammation, treatment response, 
stratification, personalized medicine
Introduction
Challenges in mental health and mood disorders
Although psychiatry has a disease-related burden greater than any single other medical 
diagnostic category,1 a disparity of esteem is still apparent between physical and 
mental health across many domains including research funding2 and publication.3 
Among the difficulties that mental health faces is a lack of consensus surrounding 
classification, diagnosis and treatment that stems from an incomplete understanding 
of the processes underlying these disorders. This is highly apparent in mood disorders, 
the category which comprises the single largest burden in mental health.3 The most 
prevalent mood disorder, major depressive disorder (MDD), is a complex, heteroge-
neous illness in which up to 60% of patients may experience some degree of treatment 
resistance that prolongs and worsens episodes.4 For mood disorders, and in the 
broader field of mental health, treatment outcomes would likely be improved by the 
discovery of robust, homogeneous subtypes within (and across) diagnostic categories, 
by which treatments could be stratified. In recognition of this, global initiatives to 
delineate functional subtypes are now in progress, such as the research domain 
criteria.5 It has been posited that biologic markers are priority candidates for subtyping 
mental disorders.6
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improving response to treatments for 
depression
Despite an extensive range of treatment options for major 
depression, only approximately a third of patients with 
MDD achieve remission even when receiving optimal 
antidepressant treatment according to consensus guidelines 
and using measurement-based care, and rates of treatment 
response appear to fall with each new treatment.7 Further-
more, treatment-resistant depression (TRD) is associated 
with increased functional impairment, mortality, morbidity 
and recurrent or chronic episodes in the long term.8,9 Thus, 
obtaining improvements in treatment response at any clinical 
stage would afford wider benefits for overall outcomes in 
depression. Despite the substantial burden attributable to 
TRD, research in this area has been sparse. Definitions of 
TRD are not standardized, in spite of previous attempts:4 
some criteria require only one treatment trial that fails to 
achieve a 50% symptom score reduction (from a validated 
measure of depression severity), while others require non-
achievement of full remission or nonresponse to at least 
two adequately trialed antidepressants of different classes 
within an episode to be considered TRD.4,10 Furthermore, 
the staging and prediction of treatment resistance is 
improved by adding the key clinical features of severity 
and chronicity to the number of failed treatments.9,11 
Nevertheless, this inconsistency in definition renders 
interpreting the research literature on TRD an even more 
complex task.
In order to improve response to treatments, it is clearly 
helpful to identify predictive risk factors of nonresponse. 
Some general predictors of TRD have been characterized, 
including a lack of full remission after previous episodes, 
comorbid anxiety, suicidality and early onset of depression, as 
well as personality (particularly low extraversion, low reward 
dependence and high neuroticism) and genetic factors.12 
These findings are corroborated by reviews synthesizing the 
evidence separately for pharmacologic13 and psychological14 
treatment for depression. Antidepressants and cognitive-
behavioral therapies show approximately comparable 
efficacy,15 but due to their differing mechanisms of action 
might be expected to have different predictors of response. 
While early-life trauma has long been associated with poorer 
clinical outcomes and reduced responses to treatment,16 early 
indications suggest that people with a history of childhood 
trauma might respond better to psychological than pharma-
cologic therapies.17 Despite this, uncertainty prevails and 
little personalization or stratification of treatment has reached 
clinical practice.18
This review focuses on the evidence supporting the utility 
of biomarkers as potentially useful clinical tools to enhance 
treatment response for depression.
Biomarkers: systems and sources
Biomarkers provide a potential target for identifying predic-
tors of response to various interventions.19 The evidence to 
date suggests that markers reflecting the activity of inflam-
matory, neurotransmitter, neurotrophic, neuroendocrine and 
metabolic systems may be able to predict mental and physical 
health outcomes in currently depressed individuals, but there 
is much inconsistency between findings.20 In this review, we 
focus on these five biologic systems.
To attain a full understanding of molecular pathways 
and their contribution in psychiatric disorders, it is now 
considered important to assess multiple biologic “levels”, 
in what is popularly referred to as an “omics” approach.21 
Figure 1 provides a depiction of the different biologic levels 
at which each of the five systems can be assessed, and the 
potential sources of markers on which these assessments can 
be undertaken. However, note that while each system can be 
inspected at each omics level, the optimal sources of measure-
ment clearly vary at each level. For example, neuroimaging 
provides a platform for indirect assessment of brain structure 
or function, while protein examinations in blood directly 
assess markers. Transcriptomics22 and metabolomics23 are 
increasingly popular, offering assessment of potentially huge 
numbers of markers, and the Human Microbiome Project 
is now attempting to identify all microorganisms and their 
genetic composition within humans.24 Novel technologies 
are enhancing our ability to measure these, including through 
additional sources; for example, hormones such as cortisol 
can now be assayed in hair or fingernails (providing a chronic 
indication) or sweat (providing a continuous measurement),25 
as well as in blood, cerebrospinal fluid, urine and saliva.
Given the number of putative sources, levels and systems 
involved in depression, it is not surprising that the scale of 
biomarkers with translational potential is extensive. Particu-
larly, when interactions between markers are considered, 
it is perhaps unlikely that examining single biomarkers in 
isolation will yield findings fruitful for improving clinical 
practice. Schmidt et al26 proposed the use of biomarker 
panels and, subsequently, Brand et al27 outlined a draft panel 
based on prior clinical and preclinical evidence for MDD, 
identifying 16 “strong” biomarker targets, each of which is 
rarely a single marker. They comprise reduced gray matter 
volume (in hippocampal, prefrontal cortex and basal ganglia 
regions), circadian cycle changes, hypercortisolism and other 
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representations of hypothalamic–pituitary–adrenal (HPA) 
axis hyperactivation, thyroid dysfunction, reduced dopamine, 
noradrenaline or 5-hydroxyindoleacetic acid, increased glu-
tamate, increased superoxide dismutase and lipid peroxida-
tion, attenuated cyclic adenosine 3′,5′-monophosphate and 
mitogen-activated protein kinase pathway activity, increased 
proinflammatory cytokines, alterations to tryptophan, 
kynurenine, insulin and specific genetic polymorphisms. 
These markers have not been agreed by consensus and could 
be measured in various ways; it is clear that focused and 
systematic work must address this enormous task in order 
to prove their clinical benefits.
Aims of this review
As a deliberately broad review, this article seeks to deter-
mine the overall needs for biomarker research in depression 
and the extent to which biomarkers hold real translational 
potential for enhancing response to treatments. We begin by 
discussing the most important and exciting findings in this 
field and direct the reader to more specific reviews pertaining 
to relevant markers and comparisons. We outline the current 
challenges faced in light of the evidence, in combination with 
needs for reducing the burden of depression. Finally, we look 
ahead to the important research pathways for meeting current 
challenges and their implications for clinical practice.
Recent insights
The search for clinically useful biomarkers for people with 
depression has generated extensive investigation over the 
last half a century. The most commonly used treatments 
were conceived from the monoamine theory of depression; 
subsequently, neuroendocrine hypotheses gained much 
attention. In more recent years, the most prolific research 
has surrounded the inflammatory hypothesis of depression. 
However, a large number of relevant review articles have 
focused across all five systems; see Table 1 and below for a 
collection of recent insights across biomarker systems. While 
measured at many levels, blood-derived proteins have been 
examined most widely and provide a source of biomarker 
that is convenient, cost-effective and may be closer to transla-
tional potential than other sources; thus, more detail is given 
to biomarkers circulating in blood.
In a recent systematic review, Jani et al20 examined 
peripheral blood-based biomarkers for depression in associa-
tion with treatment outcomes. Of only 14 studies included 
(searched up until early 2013), 36 biomarkers were studied 
of which 12 were significant predictors of mental or physical 
response indices in at least one investigation. Those identified 
as potentially representing risk factors for nonresponse 
included inflammatory proteins: low interleukin (IL)-12p70, 
ratio of lymphocyte to monocyte count; neuroendocrine 
markers (dexamethasone nonsuppression of cortisol, high 
circulating cortisol, reduced thyroid-stimulating hormone); 
neurotransmitter markers (low serotonin and noradrena-
line); metabolic (low high-density lipoprotein cholesterol) 
and neurotrophic factors (reduced S100 calcium-binding 
protein B). Further to this, other reviews have reported on 
associations between additional biomarkers and treatment 
Figure 1 Potential biomarkers for depression: biological levels, sources and systems.
Notes: See also the study by Suravajhala et al21 for further definitions and discussion around the genome (all genetic material in an organism), epigenome (all changes to 
genetic material), transcriptome (all RNA transcripts from genetics), proteome (all proteins expressed in an organism), metabolome (all small-molecule chemicals in an 
organism) and microbiome (all genes of microbes in an organism).
Abbreviation: CSF, cerebrospinal fluid.
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outcomes.19,28–30 A brief description of putative markers in 
each system is outlined in the subsequent sections and in 
Table 2.
Inflammatory findings in depression
Since Smith’s seminal paper outlining the macrophage 
hypothesis,31 this established literature has found increased 
levels of various proinflammatory markers in depressed 
patients, which have been reviewed widely.32–37 Twelve 
inflammatory proteins have been evaluated in meta-analyses 
comparing depressed and healthy control populations.38–43
IL-6 (P,0.001 in all meta-analyses; 31 studies included) 
and CRP (P,0.001; 20 studies) appear frequently and 
reliably elevated in depression.40 Elevated tumor necrosis 
factor alpha (TNFα) was identified in early studies 
(P,0.001),38 but substantial heterogeneity rendered this 
inconclusive when accounting for more recent investiga-
tions (31 studies).40 IL-1β is even more inconclusively 
associated with depression, with meta-analyses suggest-
ing higher levels in depression (P=0.03),41 high levels 
only in European studies42 or no differences from con-
trols.40 Despite this, a recent article suggested particular 
translational implications for IL-1β,44 supported by an 
extremely significant effect of elevated IL-1β ribonucleic 
acid predicting a poor response to antidepressants;45 other 
findings above pertain to circulating blood-derived cytok-
ines. The chemokine monocyte chemoattractant protein-1 
has shown elevations in depressed participants in one 
meta-analysis.39 Interleukins IL-2, IL-4, IL-8, IL-10 and 
interferon gamma were not significantly different between 
depressed patients and controls at a meta-analytic level, but 
have nonetheless demonstrated potential in terms of altering 
with treatment: IL-8 has been reported as elevated in those 
with severe depression prospectively and cross-sectionally,46 
different patterns of change in IL-10 and interferon gamma 
during treatment have occurred between early responders 
versus nonresponders,47 while IL-4 and IL-2 have decreased 
in line with symptom remission.48 In meta-analyses, small 
decreases alongside treatment have been demonstrated for 
IL-6, IL-1β, IL-10 and CRP.43,49,50 Additionally, TNFα may 
only reduce with treatment in responders, and a composite 
marker index may indicate increased inflammation in patients 
who subsequently do not respond to treatment.43 It is notable, 
however, that almost all of the research examining inflamma-
tory proteins and treatment response utilize pharmacologic 
treatment trials. Thus, at least some inflammatory alterations 
during treatment are likely attributable to antidepressants. The 
precise inflammatory effects of different antidepressants 
Table 1 Overview of recent insights into biomarkers for depression
Biomarker 
system
Review topic/summary References Evidence 
strength*
Inflammation Proinflammatory markers are higher in depression than controls Haapakoski et al40 Strong
Inflammation tends to decrease with antidepressant treatment Hiles et al50 Medium
Inflammation seems more aberrant in treatment nonresponders Strawbridge et al43 Medium
Anti-inflammatory treatments reduce depression severity Köhler et al178 Strong
Neuroendocrine HPA axis appears overactive in people with depression Horowitz and 
Zunszain190
Strong
Atypical depression may show hypocortisolism Juruena and Cleare191 Medium
High cortisol may predict a poorer response to psychological therapy and 
pharmacologic therapy
Fischer et al107
Anacker et al108
Medium
GF Some neurotrophic factors are reduced in depression compared to controls (BDNF, 
NGF, GDNF)
Molendijk et al70 Strong
Some GFs may be overproduced in depression (VEGF, bFGF) Tseng et al77 Medium
Neurotrophic factors appear to increase alongside treatment, regardless of response Castrén and Kojima192 Medium
Neurotransmitter There is widespread increased 5-HT1A binding in people with depression that can be 
influenced by treatment
Kaufman et al96 Strong
Monoamines interact to influence cognitive function and responses to stress; may provide 
mechanisms of TRD
Coplan et al99 Medium
Metabolic Depression is associated with altered metabolic profiles Pan et al193 Medium
The promise of metabolic markers for improving depression treatments is limited by the 
confounders BMi and severity
Carvalho et al194 Medium
Atypical depression linked with greater metabolic abnormalities Lamers et al156 Strong
Notes: *Strength of evidence coded as follows: weak, medium, strong, very strong, rated as per the extent of inconsistency between findings and indicated promise for the 
future of this topic. Neuroimaging (eg, Wise et al195) and genetic markers (Tamatam et al196) are reviewed extensively elsewhere.
Abbreviations: HPA, hypothalamic–pituitary–adrenal; GF, growth factor; BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; GDNF, glial cell line-derived 
neurotrophic factor; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; 5-HT1A, serotonin 1A receptor; TRD, treatment-resistant depression; 
BMi, body mass index.
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have not yet been established, but evidence using CRP levels 
suggests individuals respond differently to specific treatments 
based on baseline inflammation: Harley et al51 reported 
elevated pretreatment CRP predicting a poor response to 
psychological therapy (cognitive–behavioral or interpersonal 
psychotherapy), but a good response to nortriptyline or 
fluoxetine; Uher et al52 replicated this finding for nortriptyline 
and identified the opposite effect for escitalopram. In contrast, 
Chang et al53 found higher CRP in early responders to 
fluoxetine or venlafaxine than nonresponders. Furthermore, 
patients with TRD and high CRP have responded better to 
the TNFα antagonist infliximab than those with levels in the 
normal range.54
Together, the evidence suggests that even when control-
ling for factors such as body mass index (BMI) and age, 
inflammatory responses appear aberrant in approximately 
one-third of patients with depression.55,56 The inflammatory 
system, however, is extremely complex, and there are numer-
ous biomarkers representing different aspects of this system. 
Recently, additional novel cytokines and chemokines have 
yielded evidence of abnormalities in depression. These 
include: macrophage inhibitory protein 1a, IL-1a, IL-7, 
Table 2 Biomarkers with potential translational use for depression
Source/system Biomarker(s) with potential References
Inflammation IL-6, CRP Haapakoski et al40
TNFα Strawbridge et al43
IL-1β Farooq et al44
IL-2, IL-4, IL-10, IFNγ Dowlati et al38
IL-8, MCP1 eyre et al39
IL-1a, IFNα, IL-5, IL-7, IL-12, IL-12p70, IL-13, IL-15, IL-16, IL-17, TNFβ, MCP4, 
Mip1α, Mip1β, SAA, sICAM1, sVCAM1, eotaxin, eotaxin3, TARC, IP-10, GM-CSF
Novel markers
Growth factors BDNF Molendijk et al70
veGF Carvalho et al76
NGF Chen et al73
GDNF Lin and Tseng74
IGF-1 Tu et al83
bFGF, Tie2, sFlt1, PlGF, veGFC, veGFD, proBDNF Novel markers
Neurotransmitters 5-HT and receptors
NA, DA, glutamate/glutamine, GABA, histamine, MHPG, HvA
Kaufman et al96
Coplan et al99
Yoshimura et al197
endocrine Cortisol (various measurements) Fischer et al107
ACTH, CRH, DHeA, vasopressin Pierscionek et al198
TSH Hage and Azar199
Metabolic factors Leptin Lu88
Ghrelin wittekind and 
Kluge89
insulin Kan et al90
Albumin Maes et al93
Glucose Lustman et al92
Lipids Liu et al91
Neuroimaging 
markers
Structural, for example, gray/white matter volume wise et al195
Functional, for example, BOLD; PET ligands assessing various sources Fu et al29
Genetic GwAS/polygenic risk Ripke et al114
Telomere length Lewis116
Set of candidate gene polymorphisms; epigenetic changes to DNA 
(eg, methylation), histone modification; gene expression assessments
Dunn et al200
Notes: Nonexhaustive collection of biomarkers; many markers across systems can be observed centrally or peripherally, and at multiple levels (eg, proteomic, transcriptomic 
as well as genetic); see also accelerometer-based measurements, such as of circadian rhythms.201
Abbreviations: IL-6, interleukin-6; CRP, C-reactive protein; TNFα, tumor necrosis factor alpha; IL-1β, interleukin-1beta; IL-2, interleukin-2; IL-4, interleukin-4; IL-10, 
interleukin-10; IFNγ, interferon gamma; IL-8, interleukin-8 (CXCL8); MCP1, monocyte chemoattractant protein; IL-1α, interleukin-1alpha; IFNα, interferon alpha; IL-5, 
interleukin-5; IL-7, interleukin-7; IL-12, interleukin-12; IL-12p70, interleukin-12p70; IL-13, interleukin-13; IL-15, interleukin-15; IL-16, interleukin-16; IL-17, interleukin-17; 
TNFβ, tumor necrosis factor beta; MCP4, monocyte chemoattractant protein 4; Mip1α, macrophage inflammatory protein-1alpha; Mip1β, macrophage inflammatory 
protein-1beta; SAA, serum amyloid A; sICAM1, soluble intercellular adhesion molecule 1; sVCAM1, soluble vascular cell adhesion molecule 1; TARC, thymus and activation-
regulated chemokine; IP-10, interferon gamma-induced protein 10; GM-CSF, granulocyte macrophage colony-stimulating factor; BDNF, brain-derived neurotrophic factor; 
VEGF, vascular endothelial growth factor; NGF, nerve growth factor; GDNF, glial cell line-derived neurotrophic factor; IGF-1, insulin-like growth factor-1; bFGF, basic 
fibroblast growth factor; Tie2, tyrosine-kinase2; sFlt-1, soluble fms-like tyrosine kinase-1; PlGF, placental growth factor; 5-HT, 5-hydroxytryptamine; NA, noradrenaline; 
DA, dopamine; GABA, gamma-aminobutyric acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; HVA, homovanillic acid; ACTH, adrenocorticotropin hormone; CRH, 
corticotrophin-releasing hormone; DHEA, dehydroepiandrosterone; TSH, thyroid-stimulating hormone; BOLD, blood oxygen level dependent; PET, positron emission 
tomography; GWAS, genome-wide association study.
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IL-12p70, IL-13, IL-15, eotaxin, granulocyte macrophage 
colony-stimulating factor,57 IL-5,58 IL-16,59 IL-17,60 mono-
cyte chemoattractant protein-4,61 thymus and activation-
regulated chemokine,62 eotaxin-3, TNFb,63 interferon 
gamma-induced protein 10,64 serum amyloid A,65 soluble 
intracellular adhesion molecule66 and soluble vascular cell 
adhesion molecule 1.67
Growth factor findings in depression
In light of the potential importance of non-neurotrophic 
growth factors (such as those relating to angiogenesis), we 
refer to neurogenic biomarkers under the broader definition 
of growth factors.
Brain-derived neurotrophic factor (BDNF) is the most fre-
quently studied of these. Multiple meta-analyses demonstrate 
attenuations of the BDNF protein in serum, which appear to 
increase alongside antidepressant treatment.68–71 The most 
recent of these analyses suggests that these BDNF aberrations 
are more pronounced in the most severely depressed patients, 
but that antidepressants appear to increase the levels of this 
protein even in the absence of clinical remission.70 proBDNF 
has been less widely studied than the mature form of BDNF, 
but the two appear to differ functionally (in terms of their 
effects on tyrosine receptor kinase B receptors) and recent 
evidence suggests that while mature BDNF may be reduced 
in depression, proBDNF may be overproduced.72 Nerve 
growth factor assessed peripherally has also been reported as 
lower in depression than in controls in a meta-analysis, but 
may not be altered by antidepressant treatment despite being 
most attenuated in patients with more severe depression.73 
Similar findings have been reported in a meta-analysis for 
glial cell line-derived neurotrophic factor.74
Vascular endothelial growth factor (VEGF) has a role in 
promoting angiogenesis and neurogenesis along with other 
members of the VEGF family (eg, VEGF-C, VEGF-D) and 
has promise for depression.75 Despite inconsistent evidence, 
two meta-analyses have recently indicated elevations of 
VEGF in blood of depressed patients compared to controls 
(across 16 studies; P,0.001).76,77 However, low VEGF has 
been identified in TRD78 and higher levels have predicted 
nonresponse to antidepressant treatment.79 It is not under-
stood why the levels of VEGF protein would be elevated, 
but it may partly be attributable to proinflammatory activity 
and/or increases in blood–brain barrier permeability in 
depressed states that causes reduced expression in cerebro-
spinal fluid.80 The relationship between VEGF and treatment 
response is unclear; a recent study found no relationship 
between either serum VEGF or BDNF with response or 
depression severity, despite decreases alongside antidepres-
sant treatment.81 Insulin-like growth factor-1 is an additional 
factor with neurogenic functions that may be increased 
in depression, reflecting an imbalance in neurotrophic 
processes.82,83 Basic fibroblast growth factor (or FGF-2) is a 
member of the fibroblast growth factor family and appears 
higher in depressed than control groups.84 However, reports 
are not consistent; one found that this protein was lower in 
MDD than healthy controls, but reduced further alongside 
antidepressant treatment.85
Further growth factors that have not been sufficiently 
explored in depression include tyrosine kinase 2 and soluble 
fms-like tyrosine kinase-1 (also termed sVEGFR-1) which 
act in synergy with VEGF, and tyrosine kinase recep-
tors (that bind BDNF) may be attenuated in depression.86 
Placental growth factor is also part of the VEGF family, but 
has not been studied in systematically depressed samples to 
our knowledge.
Metabolic biomarker findings in depression
The main biomarkers associated with metabolic illness 
include leptin, adiponectin, ghrelin, triglycerides, high-
density lipoprotein (HDL), glucose, insulin and albumin.87 
The associations between many of these and depression 
have been reviewed: leptin88 and ghrelin89 appear lower in 
depression than controls in the periphery and may increase 
alongside antidepressant treatment or remission. Insulin 
resistance may be increased in depression, albeit by small 
amounts.90 Lipid profiles, including HDL-cholesterol, appear 
altered in many patients with depression, including those 
without comorbid physical illness, though this relationship 
is complex and requires further elucidation.91 Additionally, 
hyperglycemia92 and hypoalbuminemia93 in depression have 
been reported in reviews.
Investigations of overall metabolic states are becoming 
more frequent using metabolomics panels of small molecules 
with the hope of finding a robust biochemical signature for 
psychiatric disorders. In a recent study using artificial intel-
ligence modeling, a set of metabolites illustrating increased 
glucose–lipid signaling was highly predictive of an MDD 
diagnosis,94 supportive of previous studies.95
Neurotransmitter findings in depression
While the attention paid to monoamines in depression 
has yielded relatively successful treatments, no robust 
neurotransmitter markers have been identified to optimize 
treatment based on the selectivity of monoamine targets of 
antidepressants. Recent work points toward the serotonin 
 
N
eu
ro
ps
yc
hi
at
ric
 D
ise
as
e 
an
d 
Tr
ea
tm
en
t d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
92
.2
38
.1
3 
on
 1
1-
M
ay
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Neuropsychiatric Disease and Treatment 2017:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1251
Biomarkers for depression
(5-hydroxytryptamine) 1A receptor as potentially important 
for both diagnosis and prognosis of depression, pending new 
genetic and imaging techniques.96 There are new potential 
treatments targeting 5-hydroxytryptamine; for example, using 
a slow-release administration of 5-hydroxytryptophan.97 
Increased transmission of dopamine interacts with other 
neurotransmitters to improve cognitive outcomes such as 
decision making and motivation.98 Similarly, the neurotrans-
mitters glutamate, noradrenaline, histamine and serotonin 
may interact and activate as part of a depression-related stress 
response; this might decrease 5-hydroxytryptamine produc-
tion through “flooding”. A recent review sets out this theory 
and suggests that in TRD, this could be reversed (and 5-HT 
restored) through multimodal treatment targeting multiple 
neurotransmitters.99 Interestingly, increases in serotonin do 
not always occur conjunctively with therapeutic antidepres-
sant benefits.100 Despite this, neurotransmitter metabolites 
such as 3-methoxy-4-hydroxyphenylglycol, of noradrenaline, 
or homovanillic acid, of dopamine, have often been found to 
increase alongside reduction in depression with antidepres-
sant treatment101,102 or that low levels of these metabolites 
predict a better response to SSRI treatment.102,103
Neuroendocrine findings in depression
Cortisol is the most common HPA axis biomarker to have 
been studied in depression. Numerous reviews have focused 
on the various assessments of HPA activity; overall, these sug-
gest that depression is associated with hypercortisolemia and 
that the cortisol awakening response is often attenuated.104,105 
This is supported by a recent review of chronic cortisol 
levels measured in hair, supporting the hypothesis of cor-
tisol hyperactivity in depression but hypoactivity in other 
illnesses such as panic disorder.106 Furthermore, particularly, 
elevated cortisol levels may predict a poorer response to 
psychological107 and antidepressant108 treatment. Historically, 
the most promising neuroendocrine marker of prospective 
treatment response has been the dexamethasone suppression 
test, where cortisol nonsuppression following dexamethasone 
administration is associated with a lower likelihood of sub-
sequent remission. However, this phenomenon has not been 
considered sufficiently robust for clinical application. Related 
markers corticotrophin-releasing hormone and adrenocorti-
cotropin hormone as well as vasopressin are inconsistently 
found to be overproduced in depression and dehydroepi-
androsterone is found to be attenuated; the ratio of cortisol 
to dehydroepiandrosterone may be elevated as a relatively 
stable marker in TRD, persisting after remission.109 Neuroen-
docrine hormone dysfunctions have long been associated with 
depression, and hypothyroidism may also play a causal role 
in depressed mood.110 Furthermore, thyroid responses can 
normalize with successful treatment for depression.111
Within the above, it is important also to consider signal-
ing pathways across systems, such as glycogen synthase 
kinase-3, mitogen-activated protein kinase and cyclic adenos-
ine 3′,5′-monophosphate, involved in synaptic plasticity112 
and modified by antidepressants.113 Further potential bio-
marker candidates that span biologic systems particularly 
are measured using neuroimaging or genetics. In response 
to the lack of robust and meaningful genomic differences 
between depressed and nondepressed populations,114 novel 
genetic approaches such as polygenic scores115 or telomere 
length116,117 could prove more useful. Additional biomarkers 
gaining popularity are examining circadian cycles or chrono-
biologic biomarkers utilizing different sources. Actigraphy 
can provide an objective assessment of sleep and wake 
activity and rest through an accelerometer, and actigraphic 
devices can increasingly measure additional factors such as 
light exposure. This may be more useful for detection than 
commonly used subjective reports of patients and could pro-
vide novel predictors of treatment response.118 The question 
of which biomarkers are the most promising for translational 
use is a challenging one, which is expanded upon below.
Current challenges
For each of these five neurobiological systems reviewed, 
the evidence follows a similar narrative: there are many 
biomarkers that exist that are associated in some respects 
with depression. These markers are frequently interrelated 
in a complex, difficult-to-model fashion. The evidence is 
inconsistent, and it is likely that some are epiphenomena 
of other factors and some are important in only a subset of 
patients. Biomarkers are likely to be useful through a variety 
of routes (eg, those that predict subsequent response to treat-
ment, those indicating specific treatments as more likely to 
be effective or those that alter with interventions regardless 
of clinical improvements). Novel methods are required to 
maximize consistency and clinical applicability of biologic 
assessments in psychiatric populations.
Biomarker variability
Variation of biomarkers over time and across situations 
pertains more to some types (eg, proteomics) than others 
(genomics). Standardized norms for many do not exist or 
have not been widely accepted. Indeed, the influence of 
environmental factors on markers frequently depends on 
genetic composition and other physiologic differences between 
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people that cannot all be accounted for. This makes the 
assessment of biomarker activity, and identifying biologic 
abnormalities, difficult to interpret. Due to the number of 
potential biomarkers, many have not been measured widely 
or in a complete panel alongside other relevant markers.
Many factors have been reported to alter the protein 
levels across biologic systems in patients with affective dis-
orders. Along with research-related factors such as duration 
and conditions of storage (which may cause degradation 
of some compounds), these include time of day measured, 
ethnicity, exercise,119 diet (eg, microbiome activity, espe-
cially provided that most blood biomarker studies do not 
require a fasting sample),120 smoking and substance use,121 
as well as health factors (such as comorbid inflammatory, 
cardiovascular or other physical illnesses). For example, 
although heightened inflammation is observed in depressed 
but otherwise healthy individuals compared to nondepressed 
groups, depressed individuals who also have a comorbid 
immune-related condition frequently have even higher levels 
of cytokines than either those without depression or illness.122 
Some prominent factors with probable involvement in the 
relationship between biomarkers, depression and treatment 
response are outlined below.
Stress
Both endocrine and immune responses have well-known roles 
in responding to stress (physiologic or psychological), and 
transient stress at the time of biologic specimen collection is 
rarely measured in research studies despite the variability of 
this factor between individuals that may be accentuated by 
current depressive symptoms. Both acute and chronic psy-
chological stressors act as an immune challenge, accentuating 
inflammatory responses in the short and longer term.123,124 This 
finding extends to the experience of early-life stress, which 
has been associated with adult inflammatory elevations that 
are independent of stress experienced as an adult.125,126 During 
childhood traumatic experience, heightened inflammation has 
also been reported only in those children who were currently 
depressed.127 Conversely, people with depression and a history 
of childhood trauma may have blunted cortisol responses to 
stress, compared to those with depression and no early-life 
trauma.128 Stress-induced HPA axis alterations appear interre-
lated with cognitive function,129 as well as depression subtype 
or variation in HPA-related genes.130 Stress also has short- 
and long-term impairing effects on neurogenesis131 and other 
neural mechanisms.132 It is unclear precisely how childhood 
trauma affects biologic markers in depressed adults, but it is 
possible that early-life stress predisposes some individuals 
to enduring stress reactions in adulthood that are amplified 
psychologically and/or biologically.
Cognitive functioning
Neurocognitive dysfunctions occur frequently in people 
with affective disorders, even in unmedicated MDD.133 
Cognitive deficits appear cumulative alongside treatment 
resistance.134 Neurobiologically, the HPA axis129 and neu-
rotrophic systems135 are likely to play a key role in this 
relationship. Neurotransmitters noradrenaline and dopamine 
are likely important for cognitive processes such as learn-
ing and memory.136 Elevated inflammatory responses have 
been linked with cognitive decline, and likely affect cogni-
tive functioning in depressive episodes,137 and in remission, 
through a variety of mechanisms.138 Indeed, Krogh et al139 
proposed that CRP is more closely related to cognitive per-
formance than to the core symptoms of depression.
Age, gender and BMi
The absence or presence, and direction of biologic differences 
between men and women has been particularly variable in the 
evidence to date. Neuroendocrine hormone variation between 
men and women interacts with depression susceptibility.140 
A review of inflammation studies reported that controlling 
for age and gender did not affect patient-control differences 
in inflammatory cytokines (although the association between 
IL-6 and depression reduced as age increased, which is 
consistent with theories that inflammation generally height-
ens with age).41,141 VEGF differences between patients and 
controls are larger in studies assessing younger samples, 
while gender, BMI and clinical factors did not affect these 
comparisons at a meta-analytic level.77 However, the lack of 
adjustment for BMI in previous examinations of inflamma-
tion and depression appears to confound highly significant 
differences reported between these groups.41 Enlarged adi-
pose tissue has been definitively demonstrated to stimulate 
cytokine production as well as being closely linked to meta-
bolic markers.142 Because psychotropic medications may be 
associated with weight gain and a higher BMI, and these have 
been associated with treatment resistance in depression, this 
is an important area to examine.
Medication
Many biomarker studies in depression (both cross-sectional 
and longitudinal) have collected baseline specimens in 
unmedicated participants to reduce heterogeneity. However, 
many of these assessments are taken after a wash-out period 
from medication, which leaves the potentially significant 
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confounding factor of residual changes in physiology, exac-
erbated by the extensive range of treatments available that 
may have had differing effects on inflammation. Some studies 
have excluded psychotropic, but not other medication use: in 
particular, the oral contraceptive pill is frequently permitted 
in research participants and not controlled for in analyses, 
which has recently been indicated to increase hormone 
and cytokine levels.143,144 Several studies indicate that 
antidepressant medications have effects on the inflammatory 
response,34,43,49,145–147 HPA-axis,108 neurotransmitter,148 and 
neurotrophic149 activity. However, the numerous potential 
treatments for depression have distinct and complex pharma-
cologic properties, suggesting there may be discrete biologic 
effects of different treatment options, supported by current 
data. It has been theorized that in addition to monoamine 
effects, specific serotonin-targeting medications (ie, SSRIs) 
are likely to target Th2 shifts in inflammation, and noradren-
ergic antidepressants (eg, SNRIs) effect a Th1 shift.150 It is not 
yet possible to determine the effects of individual or combina-
tion medications on biomarkers. These are likely mediated 
by other factors including the length of treatment (few trials 
assess long-term medication use), sample heterogeneity and 
not stratifying participants by response to treatment.
Heterogeneity
Methodological
As alluded to above, differences (between and within studies) 
in terms of which treatments (and combinations) the par-
ticipants are taking and have taken previously are bound 
to introduce heterogeneity into research findings, particu-
larly in biomarker research. In addition to this, many other 
design and sample characteristics vary across studies, thus 
augmenting the difficulty with interpreting and attributing 
findings. These include biomarker measurement parameters 
(eg, assay kits) and methods of collecting, storing, processing 
and analyzing markers in depression. Hiles et al141 examined 
some sources of inconsistency in the literature on inflamma-
tion and found that accuracy of depression diagnosis, BMI 
and comorbid illnesses were most important to account for 
in assessing peripheral inflammation between depressed and 
nondepressed groups.
Clinical
The extensive heterogeneity of depressed populations is well 
documented151 and is a critical contributor to contrasting 
findings within the research literature. It is probable that even 
within diagnoses, abnormal biologic profiles are confined 
to subsets of individuals that may not be stable over time. 
Cohesive subgroups of people suffering with depression 
may be identifiable through a combination of psychological 
and biologic factors. Below, we outline the potential for 
exploring subgroups in meeting the challenges that biomarker 
variability and heterogeneity pose.
Subtypes within depression
Thus far, no homogenous subgroups within depression 
episodes or disorders have been reliably able to distinguish 
between patients based on symptom presentations or treat-
ment responsiveness.152 The existence of a subgroup in whom 
biologic aberrations are more pronounced would help to 
explain the heterogeneity between previous studies and could 
catalyze the path toward stratified treatment. Kunugi et al153 
have proposed a set of four potential subtypes based on the 
role of different neurobiological systems displaying clinically 
relevant subtypes in depression: those with hypercortisolism 
presenting with melancholic depression, or hypocortisolism 
reflecting an atypical subtype, a dopamine-related subset 
of patients who may present prominently with anhedonia 
(and could respond well to, eg, aripiprazole) and an inflam-
matory subtype characterized by elevated inflammation. 
Many articles focusing on inflammation have specified the 
case for the existence of an “inflammatory subtype” within 
depression.55,56,154,155 Clinical correlates of elevated inflam-
mation are as yet undetermined and few direct attempts have 
been made to discover which participants may comprise 
this cohort. It has been proposed that people with atypical 
depression could have higher levels of inflammation than 
the melancholic subtype,156 which is perhaps not in line with 
findings regarding the HPA axis in melancholic and atypical 
subtypes of depression. TRD37 or depression with prominent 
somatic symptoms157 has also been posited as a potential 
inflammatory subtype, but neurovegetative (sleep, appetite, 
libido loss), mood (including low mood, suicidality and 
irritability) and cognitive symptoms (including affective bias 
and guilt)158 all appear related to biologic profiles. Further 
potential candidates for an inflammatory subtype involve 
the experience of sickness behavior-like symptoms159,160 or 
a metabolic syndrome.158
The propensity toward (hypo) mania may distinguish 
biologically between patients suffering from depression. 
Evidence now suggests that bipolar illnesses are a multifaceted 
group of mood disorders, with bipolar subsyndromal disorder 
found more prevalently than was previously recognized.161 
Inaccurate and/or delayed detection of bipolar disorder has 
recently been highlighted as a major problem in clinical psy-
chiatry, with the average time to correct diagnosis frequently 
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exceeding a decade162 and this delay causing greater severity 
and cost of overall illness.163 With the majority of patients 
with bipolar disorder presenting initially with one or more 
depressive episodes and unipolar depression being the most 
frequent misdiagnosis, the identification of factors that might 
differentiate between unipolar and bipolar depression has 
substantial implications.164 Bipolar spectrum disorders likely 
have been undetected in some previous MDD biomarker 
investigations, and smatterings of evidence have indicated 
differentiation of HPA axis activity109 or inflammation165,166 
between bipolar and unipolar depression. However, these 
comparisons are scarce, possess small sample sizes, identified 
nonsignificant trend effects or recruited populations that were 
not well characterized by diagnosis. These investigations 
also do not examine the role of treatment responsiveness in 
these relationships.
Both bipolar disorders167 and treatment resistance168 
are not dichotomous constructs and lie on continua, which 
increases the challenge of subtype identification. Apart from 
subtyping, it is worth noting that many biologic abnormalities 
observed in depression are similarly found in patients with 
other diagnoses. Thus, transdiagnostic examinations are also 
potentially important.
Biomarker measurement challenges
Biomarker selection
The large number of potentially useful biomarkers presents 
a challenge for psychobiology in determining which markers 
are implicated in which way and for whom. To increase the 
challenge, relatively few of these biomarkers have been 
subject to sufficient investigation in depression, and for 
most, their precise roles in healthy and clinical populations 
are not well understood. Despite this, a number of attempts 
have been made to propose promising biomarker panels. 
In addition to Brand et al’s 16 sets of markers with strong 
potential,27 Lopresti et al outline an additional extensive set 
of oxidative stress markers with potential for improving 
treatment response.28 Papakostas et al defined a priori a set 
of nine serum markers spanning biologic systems (BDNF, 
cortisol, soluble TNFα receptor type II, alpha1 antitrypsin, 
apolipoprotein CIII, epidermal growth factor, myeloper-
oxidase, prolactin and resistin) in validation and replication 
samples with MDD. Once combined, a composite measure 
of these levels was able to distinguish between MDD and 
control groups with 80%–90% accuracy.169 We propose that 
even these do not cover all potential candidates in this field; 
see Table 2 for a nonexhaustive delineation of biomarkers 
with potential for depression, containing both those with an 
evidence base and promising novel markers.
Technology
Due to technologic advances, it is now possible (indeed, 
convenient) to measure a large array of biomarkers simulta-
neously at a lower cost and with higher sensitivity than 
has been the case previously. At present, this capability 
to measure numerous compounds is ahead of our ability 
to effectively analyze and interpret the data,170 some-
thing that will continue with the rise in biomarker arrays 
and new markers such as with metabolomics. This is 
largely due to a lack of understanding about the precise 
roles of and the interrelationships between markers, and 
an insufficient grasp of how related markers associate 
across different biologic levels (eg, genetic, transcrip-
tion, protein) within and between individuals. Big data 
using new analytical approaches and standards will assist 
with addressing this, and new methodologies are being 
proposed; one example is the development of a statistical 
approach grounded in flux-based analysis to discover new 
potential metabolic markers based on their reactions between 
networks and integrate gene expression with metabolite 
data.171 Machine learning techniques are already being 
applied and will assist with models using biomarker data 
to predict treatment outcomes in studies with big data.172
Aggregating biomarkers
Examining an array of biomarkers simultaneously is an 
alternative to inspecting isolated markers that could provide 
a more accurate viewpoint into the complex web of biologic 
systems or networks.26 Also, to assist with disentangling con-
trasting evidence in this literature to date (particularly, where 
biomarker networks and interactions are well understood), 
biomarker data can then be aggregated or indexed. One chal-
lenge is in identifying the optimum method of conducting 
this, and it may require enhancements in technology and/or 
novel analytical techniques (see the “Big data” section). 
Historically, ratios between two distinct biomarkers have 
yielded interesting findings.109,173 Few attempts have been 
made to aggregate biomarker data on a larger scale, such as 
those using principal component analysis of proinflammatory 
cytokine networks.174 In a meta-analysis, proinflammatory 
cytokines have been converted into a single-effect size 
score for each study, and overall showed significantly higher 
inflammation before antidepressant treatment, predicting 
subsequent nonresponse in outpatient studies. Composite 
biomarker panels are both a challenge and opportunity for 
future research to identify meaningful and reliable findings 
that can be applied to improve treatment outcomes.43 A study 
by Papakostas et al took an alternative approach, selecting a 
panel of heterogeneous serum biomarkers (of inflammatory, 
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HPA axis and metabolic systems) that had been indicated to 
differ between depressed and control individuals in a previous 
study and composited these into a risk score which differed 
in two independent samples and a control group with .80% 
sensitivity and specificity.169
Big data
The use of big data is probably necessary for addressing 
the current challenges outlined surrounding heterogeneity, 
biomarker variability, identifying the optimal markers and 
bringing the field toward translational, applied research 
in depression. However, as outlined above, this brings 
technological and scientific challenges.175 The health sciences 
have only recently begun using big data analytics, a decade 
or so later than in the business sector. However, studies such 
as iSPOT-D152 and consortia such as the Psychiatric Genetics 
Consortium176 are progressing with our understanding of 
biologic mechanisms in psychiatry. Machine-learning algo-
rithms have, in very few studies, started to be applied to 
biomarkers for depression: a recent investigation pooled data 
from .5,000 participants of 250 biomarkers; after multiple 
imputation of data, a machine-learning boosted regression 
was conducted, indicating 21 potential biomarkers. Following 
further regression analyses, three biomarkers were selected as 
associating most strongly with depressive symptoms (highly 
variable red blood cell size, serum glucose and bilirubin 
levels). The authors conclude that big data can be used 
effectively for generating hypotheses.177 Larger biomarker 
phenotyping projects are now underway and will help to 
advance our journey into the future of the neurobiology 
of depression.
Future prospects
Biomarker panel identification
The findings in the literature to date require replication 
in large-scale studies. This is particularly true for novel 
biomarkers, such as the chemokine thymus and activation-
regulated chemokine and the growth factor tyrosine kinase 
2 which, to our knowledge, have not been investigated in 
clinically depressed and healthy control samples. Big data 
studies must assay comprehensive biomarker panels and 
use sophisticated analysis techniques to fully ascertain the 
relationships between markers and those factors which 
modify them in clinical and nonclinical populations. Addi-
tionally, large-scale replications of principal component 
analysis might establish highly correlated groups of bio-
markers and could also inform the use of “composites” in 
biologic psychiatry, which may enhance the homogeneity 
of future findings.
Discovery of homogenous subtypes
Regarding biomarker selection, multiple panels may be 
required for different potential pathways that research could 
implicate. Taken together, the current evidence indicates that 
biomarker profiles are assuredly, but abstrusely altered in a 
subpopulation of individuals currently suffering from depres-
sion. This may be established within or across diagnostic 
categories, which would account for some inconsistency of 
findings that can be observed in this literature. Quantifying 
a biologic subgroup (or subgroups) may most effectively be 
facilitated by a large cluster analysis of biomarker network 
panels in depression. This would illustrate within-population 
variability; latent class analyses could exhibit distinct clinical 
characteristics based on, for example, inflammation.
Specific treatment effects on inflammation 
and response
All commonly prescribed treatments for depression should be 
comprehensively assessed for their specific biologic effects, 
also accounting for the effectiveness of treatment trials. This 
may enable constructs relating to biomarkers and symptom 
presentations to predict outcomes to a variety of antidepres-
sant treatments in a more personalized fashion, and may be 
possible in the context of both unipolar and bipolar depres-
sion. This is likely to be useful for new potential treatments 
as well as currently indicated treatments.
Prospective determination of treatment 
response
Use of the above techniques is likely to result in an improved 
ability to forecast treatment resistance prospectively. More 
authentic and persistent (eg, long-term) measures of treatment 
response may contribute to this. Assessment of other valid 
measures of patient well-being (such as quality of life and 
everyday functioning) could provide a more holistic assess-
ment of treatment outcome that may associate more closely 
with biomarkers. While biologic activity alone might not be 
able to distinguish treatment responders from nonresponders, 
concurrent measurement of biomarkers with psychosocial or 
demographic variables could be integrated with biomarker 
information in developing a predictive model of insufficient 
treatment response. If a reliable model is developed to predict 
response (either for the depressed population or a subpopula-
tion) and is validated retrospectively, a translational design 
can establish its applicability in a large controlled trial.
Toward stratified treatments
At present, patients with depression are not systematically 
directed to receive an optimized intervention program. 
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If validated, a stratified trial design could be employed to test 
a model to predict nonresponse and/or to determine where 
a patient needs to be triaged in a stepped care model. This 
could be useful in both standardized and naturalistic treatment 
settings, across different types of intervention. Ultimately, 
a clinically viable model could be developed to provide 
individuals with the most appropriate treatment, to recognize 
those who are likely to develop refractory depression and sup-
ply enhanced care and monitoring to these patients. Patients 
identified as being at risk for treatment resistance may be 
prescribed a concomitant psychological and pharmacologic 
therapy or combination pharmacotherapy. As a speculative 
example, participants with no proinflammatory cytokine 
elevations might be indicated to receive psychological 
rather than pharmacologic therapy, while a subset of patients 
with particularly high inflammation could receive an anti-
inflammatory agent in augmentation to standard treatment. 
Similar to stratification, personalized treatment-selection 
strategies may be possible in the future. For example, a 
particular depressed individual might have markedly high 
TNFα levels, but no other biologic abnormalities, and could 
benefit from short-term treatment with a TNFα antagonist.54 
Personalized treatment may also entail monitoring biomarker 
expression during treatment to inform possible intervention 
changes, the length of continuation therapy required or to 
detect early markers of relapse.
Novel treatment targets
There are a huge number of potential treatments that could 
be effective for depression, which have not been adequately 
examined, including novel or repurposed interventions 
from other medical disciplines. Some of the most popular 
targets have been in anti-inflammatory medications such as 
celecoxib (and other cyclooxygenase-2 inhibitors), TNFα 
antagonists etanercept and infliximab, minocycline or aspirin. 
These appear promising.178 Antiglucocorticoid compounds, 
including ketoconazole179 and metyrapone,180 have been inves-
tigated for depression, but both have drawbacks with their 
side effect profile and the clinical potential of metyrapone 
is uncertain. Mifepristone181 and the corticosteroids fludro-
cortisone and spironolactone,182 and dexamethasone and 
hydrocortisone183 may also be effective in treating depression 
in the short term. Targeting glutamate N-methyl-d-aspartate 
receptor antagonists, including ketamine, might represent 
efficacious treatments in depression.184 Omega-3 polyun-
saturated fatty acids influence inflammatory and metabolic 
activity and appear to demonstrate some effectiveness for 
depression.185 It is possible that statins may have antidepres-
sant effects186 through relevant neurobiological pathways.187
In this way, the biochemical effects of antidepressants 
(see the “Medication” section) have been utilized for clinical 
benefits in other disciplines: particularly gastroenterological, 
neurologic and nonspecific symptom illnesses.188 Anti-
inflammatory effects of antidepressants may represent 
part of the mechanism for these benefits. Lithium has also 
been suggested to reduce inflammation, critically through 
glycogen synthase kinase-3 pathways.189 A focus on these 
effects could prove informative for a depression biomarker 
signature and, in turn, biomarkers could represent surrogate 
markers for novel drug development.
Conclusion
The literature indicates that approximately two-thirds of 
patients with depression do not achieve remission to an initial 
treatment and that the likelihood of nonresponse increases 
with the number of treatments trialed. Providing ineffective 
therapies has substantial consequences for individual and 
societal cost, including persistent distress and poor well-
being, risk of suicide, loss of productivity and wasted health 
care resources. The vast literature in depression indicates a 
huge number of biomarkers with the potential to improve 
treatment for people with depression. In addition to neu-
rotransmitter and neuroendocrine markers which have been 
subject to widespread study for many decades, recent insights 
highlight the inflammatory response (and the immune system 
more generally), metabolic and growth factors as importantly 
involved in depression. However, excessive contrasting evi-
dence illustrates that there are a number of challenges need-
ing to be tackled before biomarker research can be applied 
in order to improve the management and care of people 
with depression. Due to the sheer complexity of biologic 
systems, simultaneous examinations of a comprehensive 
range of markers in large samples are of considerable benefit 
in discovering interactions between biologic and psychologi-
cal states across individuals. Optimizing the measurement 
of both neurobiological parameters and clinical measures 
of depression is likely to facilitate greater understanding. 
This review also highlights the importance of examining 
potentially modifying factors (such as illness, age, cognition 
and medication) in gleaning a coherent understanding of the 
biology of depression and mechanisms of treatment resis-
tance. It is likely that some markers will show most promise 
for predicting treatment response or resistance to specific 
treatments in a subgroup of patients, and the concurrent mea-
surement of biologic and psychological data may enhance 
the ability to prospectively identify those at risk for poor 
treatment outcomes. Establishing a biomarker panel has 
implications for boosting diagnostic accuracy and prognosis, 
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as well as for individualizing treatments at the earliest prac-
ticable stage of depressive illness and developing effective 
novel treatment targets. These implications may be confined 
to subgroups of depressed patients. The pathways toward 
these possibilities complement recent research strategies to 
link clinical syndromes more closely to underlying neuro-
biological substrates.6 Apart from reducing heterogeneity, 
this may facilitate a shift toward parity of esteem between 
physical and mental health. It is clear that although much 
work is needed, establishment of the relationship between 
relevant biomarkers and depressive disorders has substantial 
implications for reducing the burden of depression at an 
individual and societal level.
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